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Among the different signaling molecules released during reactive gliosis occurring in Alzheimer’s disease (AD), the astrocyte-
derived S100B protein plays a key role in neuroinflammation, one of the hallmarks of the disease. The use of pharmacological
tools targeting S100B may be crucial to embank its effects and some of the pathological features of AD. The antiprotozoal drug
pentamidine is a good candidate since it directly blocks S100B activity by inhibiting its interaction with the tumor suppressor p53.
We used a mouse model of amyloid beta- (A𝛽-) induced AD, which is characterized by reactive gliosis and neuroinflammation in
the brain, and we evaluated the effect of pentamidine on the main S100B-mediated events. Pentamidine caused the reduction of
glial fibrillary acidic protein, S100B, and RAGE protein expression, which are signs of reactive gliosis, and induced p53 expression in
astrocytes. Pentamidine also reduced the expression of proinflammatorymediators andmarkers, thus reducing neuroinflammation
in AD brain. In parallel, we observed a significant neuroprotection exerted by pentamidine on CA1 pyramidal neurons. We
demonstrated that pentamidine inhibits A𝛽-induced gliosis and neuroinflammation in an animal model of AD, thus playing a
role in slowing down the course of the disease.
1. Introduction
Alzheimer’s disease (AD) is the most common age-related
neurodegenerative disorder [1], whose pathologic hallmarks
are the deposit of neurofibrillary tangles and senile plaques
(beta-amyloid protein deposits) in the brain [2, 3]. Increasing
evidence demonstrates that inflammation in the brain, specif-
ically neuroinflammation, plays a key role in the development
of AD [4, 5]. This pathologic event is accompanied by the
activation of glial cells in the brain, a phenomenon known as
“reactive gliosis” [6]. In fact, it has been shown that amyloid-
beta- (A𝛽-) induced reactive gliosis and the consequent
inflammatory responses with the release of neurotoxic cytok-
ines are present in the AD brain and prominently contribute
to the progression of the disease [7]. The two events are thus
thoroughly linked and are object of the current research on
AD pathophysiology.
The definition of “reactive gliosis” refers to the overex-
pression of glial-derived factors. Amongst all, one of themost
interesting from a pharmacological point of view is the pro-
tein S100B [8, 9].This small and soluble protein, belonging to
the large family of EF-related Ca++- and Zn++-binding pro-
teins, plays a dual effect. While at nanomolar concentrations
S100B provides to a prosurvival effect on neurons and stim-
ulates neurite outgrowth, at higher (micromolar) concentra-
tions it promotes inflammation and neuronal apoptosis [10].
S100B overexpression has been linked to the typical features
of reactive gliosis inAD [11, 12]. After release, and onlywhen it
reaches micromolar concentrations, the protein accumulates
at the RAGE (receptor for advanced glycation end-products)
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surface [13–15]. Such interaction leads to the phosphorylation
of mitogen-activated protein kinase (MAPK) and the activa-
tion of nuclear factor-kappaB (NF-𝜅B).This cascade, in turn,
promotes the transcription of proinflammatory cytokines
and inducible nitric oxide synthase (iNOS) protein [16]. The
possibility of interfering with this harmful cycle, by directly
targeting S100B, might therefore represent a novel approach
to embank neurotoxicity in AD brain.
Pentamidine isethionate, discovered in 1938 as an antipro-
tozoal drug and approved in the United States for the treat-
ment of Pneumocystis carinii pneumonia and other protozoal
diseases [17], appears to be an intriguing candidate. In fact,
in addition to the antiprotozoal activity, pentamidine also
inhibits S100B-mediated effects because of its ability to block
S100B/p53 interaction [18]. In spite of the several data show-
ing the anti-inflammatory effect exerted by pentamidine due
to S100B inhibition [19–22], no data on the possible effect
of pentamidine on gliosis and neuroinflammation in AD
models are available so far.
Based on this background, the present study was aimed at
evaluating the effect of a daily intrahippocampal administra-
tion of pentamidine in a mouse model of AD characterized
by A𝛽-induced gliosis and neuroinflammation. Because of
the capability to inhibit S100B protein, we investigated (1) the
effect exerted by pentamidine on reactive gliosis, (2) the
molecular mechanism by which pentamidine might interfere
with reactive gliosis, and (3) whether pentamidine-mediated
inhibition of reactive gliosis may result in the rescue of
neuronal loss in AD brain.
2. Methods
2.1. Ethics Statement. All the experiments were performed in
accordance with the National Institutes of Health Guidelines
for the Care and Use of Laboratory Animals (Institute of
Laboratory Animal Resources, 1996) and those of the Italian
Ministry of Health (D.L. 116/92). The study was approved by
the Institutional local Animal Care and Use Committees.
2.2. Animals. Experiments were performed in C57BL/6J
mice (3–5 months old, weight range: 35–40 g; Harlan, Udine,
Italy). Animals were housed under controlled illumination
(12 h light/12 h dark cycle) and standard environmental
conditions (room temperature 20–22∘C, humidity 55–60%).
Food and water were available ad libitum. All surgery and
experimental procedures were performed during the light
cycle. All efforts were made to reduce the number of animals
used and the suffering during surgical experiments.
2.3. Surgical Preparation and Intrahippocampal Injection.
Mice (total 𝑛 = 40) were anesthetized i.p. with pentobarbital
(40mg/kg).They were then placed in a stereotaxic frame and
injected in the hippocampi (CA1 area) with human A𝛽 (1–
42) peptide (Tocris Cookson, UK). The coordinates for the
injection were −1.58mm posterior from bregma, ±1.2mm
lateral and 1.60mm ventral to the skull surface. A𝛽 peptide
was dissolved in ALZET artificial cerebrospinal fluid accord-
ing to the manufacturer’s instructions (ALZET-company,
Cupertino, CA, USA). The final concentration was 10 𝜇g/mL
and a volume of 3 𝜇L was injected using an ALZET micro-
dialysis pump by keeping the flow at the constant speed of
0.5mL/min. Control mice (vehicle-treated group, 𝑛 = 8)
were injected with an equivalent volume of artificial cere-
brospinal fluid. Starting at the third day after surgery and
using the previously implanted cannula, three groups of mice
(𝑛 = 8 per group) received intrahippocampal infusion of pen-
tamidine (0.05–5 𝜇g/mL/day) for consecutive 7 days. At the
end of treatments, the cannula was removed and the animals,
to prevent damage to the scalp sutures, were kept in individ-
ual cages until they were killed for tissue processing.
2.4. Immunohistochemistry and Immunofluorescence Anal-
yses. Immunohistochemistry analysis was performed on
hippocampal coronal sections (adjacent to the site of the
injection) obtained from the brains of vehicle-, A𝛽-, and
pentamidine-treated mice. Sections were incubated for 2
hours with blocking buffer (PBS containing 15mM NaN
3
,
10% albumin, and 0.25% Triton X-100) and then with mouse
anti-GFAP antibody (1 : 400, Sigma-Aldrich, Milan, Italy)
overnight at 4∘C. Biotinylated secondary antibody (1 : 200;
Vector Laboratories, Peterborough, UK) and the preformed
avidin biotinylated peroxidase complex (VECTASTAINABC
kit; Vector Laboratories) were then added and the reac-
tion was revealed by 3,3-diaminobenzidine tetrahydrochlo-
ride (Sigma-Aldrich). Representative pictures were captured
using a high-resolution digital camera (Nikon Digital Sight
DS-U1).
For the immunofluorescence, hippocampal coronal sec-
tions obtained from the brains of vehicle-, A𝛽-, and pentami-
dine-treated mice were blocked in 10% albumin bovine
serum 0.1% Triton-PBS solution for 90min and subsequently
exposed for 1 h to rabbit anti-GFAPantibody (1 : 1000,Abcam,
Cambridge, UK) and mouse anti-p53 antibody (1 : 500,
Abcam). Sections were then incubated in the dark with the
proper secondary antibody: fluorescein isothiocyanate-con-
jugated anti-rabbit (1 : 1000, Abcam) or Texas Red-conjugated
anti-mouse (1 : 1000, Abcam), respectively. Immunofluores-
cence was analyzed with a Nikon Eclipse 80i microscope
(Nikon Instruments Europe, Kingston upon Thames, UK)
and images were captured by a high-resolution digital camera
(Nikon Digital Sight DS-U1). The number of GFAP+ or p53+
cells was then calculated in every tenth coronal section span-
ning the ipsilateral hippocampus at the injection site using
unbiased stereology (Stereo Investigator, MBF,Williston, VT,
USA). According to the manufacturer’s protocol, a counting
frame (15 × 15 × 20 𝜇m) was placed at the intersection of
a matrix (200 × 200 𝜇m) randomly superimposed by the
software onto the region of interest.
2.5. Nissl Staining. Hippocampal coronal sections (𝑛 = 5)
obtained from the brains of vehicle-, A𝛽-, and pentamidine-
treated mice were sequentially dipped in different alcohol
solutions of decreasing percentage to remove lipids from the
tissue, stained with 2% cresyl violet solution for 5 minutes,
and dehydrated with a series of baths with increasing alcohol
percentage solutions. Sections were analyzed by a blind
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observer through a Nikon Eclipse 80i microscope. Represen-
tative pictures were captured using a high-resolution digital
camera (NikonDigital Sight DS-U1) and analyzed using NIS-
Elements software (Nikon Instruments Europe). The extent
of neuronal damage was expressed as the ratio between the
number of nonstained (death) neurons and the total number
of neurons permmof length ofCA1 area in injected ipsilateral
hippocampi, according with the following formula:
death neurons per CA1 mm2 area
total neurons per CA1mm2 area
= extent of CA1 damage (%) .
(1)
2.6. Fluoro-Jade B Staining. To further evaluate neuronal
loss/rescue in the hippocampus, Fluoro-Jade B (FJB) staining
was performed on hippocampal coronal sections obtained
from the brains of vehicle-, A𝛽-, and pentamidine-treated
mice. Sectionswere immersed in a basic alcoholic solution for
6 minutes and 0.06% KMnO
4
for 15 minutes. Sections were
then incubated in 0.0004% FJB (Histo-Chem, Jefferson, AR,
USA) for 20 minutes, washed in distilled water, and then
dried. To quantify neuronal death, every tenth coronal sec-
tion spanning hippocampus was analyzed from each animal
(𝑛 = 5). A blinded observer counted the number of FJB-
positive neurons in the hippocampal CA1 from ipsilateral
hemispheres to the injection site. Mean counts of FJB-
positive neurons from each regionwere used for the statistical
analysis.
2.7. Immunoblot Analysis. Ipsilateral hippocampi to the injec-
tion site were dissected from frozen excised brains of vehicle-,
A𝛽-, and pentamidine-treated mice and lysed with ice-
cold hypotonic lysis buffer (Tris/HCl pH 7.5 50mM; NaCl
150mM; EDTA 1mM; Triton X-100 1%) supplemented with
the proper protease inhibitor cocktail (Roche, Milan, Italy)
and incubated on ice for additional 15min. Total protein
extracts were obtained by centrifugation at 13,000 g for 15min
at 4∘C. Samples were subjected to SDS-polyacrylamide gel
electrophoresis and proteins were transferred onto nitrocel-
lulose membrane and incubated with one of the following
antibodies: anti-GFAP (1 : 50000); anti-iNOS (1 : 200); anti-
COX-2 (1 : 1000), anti-phospho(p)-p38 MAPK (1 : 400), anti-
RAGE (1 : 1000), and anti-𝛽-actin (1 : 2000) (all fromAbcam).
After wash in TBS 1X with 0.1% Tween 20, themembrane was
incubated for 2 h at room temperature with the appropriate
secondary HRP-conjugated antibodies anti-mouse (1 : 1000,
Abcam) or anti-rabbit (1 : 1000, Abcam). Lastly, the mem-
brane was exposed to the enhanced chemiluminescence
substrate (ECL, Invitrogen,Milan, Italy), the immunoreactive
bands were revealed through a Versadoc (Bio-Rad Laborato-
ries, Milan, Italy) and the digital images were analyzed with
the Quantity One Software (Bio-Rad Laboratories).
2.8. Electrophoretic Mobility Shift Assay (EMSA). EMSA was
performed to detect NF-𝜅B activation in hippocampal
homogenates obtained from the brains of vehicle-, A𝛽-, and
pentamidine-treatedmice. Double stranded oligonucleotides
containing NF-𝜅B recognition sequence (5󸀠AGTTGAGGG-
GACTTTCCCAGGC-3󸀠) were end-labeled with 32P-𝛾-ATP
(Amersham, Milan, Italy). Nuclear extracts were incubated
for 15min with radiolabeled oligonucleotides (2.5–5.0 ×
104 cpm) in 20mL reaction buffer containing 2mg poly dI-
dC (Boehringer-Mannheim, Milan, Italy), 10mM Tris–HCl
(pH 7.5), 100mMNaCl, 1mM EDTA, 1mM dl-dithiothreitol,
1mg/mL bovine serum albumin, and 10% glycerol. Nuclear
protein-oligonucleotide complexes were resolved by elec-
trophoresis on a 6% nondenaturing polyacrylamide gel in 1X
Tris Borate EDTA buffer at 150V for 2 hrs at 4∘C. The gel
was dried and autoradiographed with an intensifying screen
at−80∘C for 20 h. Subsequently, the relative bandswere quan-
tified by densitometric scanning with Versadoc (Bio-Rad
Laboratories) and computer software (QuantityOne Software,
Bio-Rad Laboratories). Oligonucleotide synthesis was per-
formed to our specifications by Tib Molbiol (Boehringer-
Mannheim, Ingelheim am Rhein, Germany).
2.9. Nitrite Assay. NO was measured as nitrite (NaNO
2
)
accumulation in mice hippocampal homogenates, obtained
from the brains of vehicle-, A𝛽-, and pentamidine-treated
mice, by using the Griess method [23]. Briefly, Griess reagent
(1% sulphanilamide, 0.1% naphthylethylenediamine in
H
3
PO
4
) was added to an equal volume of tissue homogenate
and the absorbance of the reaction product was measured
at 550 nm. Nitrite concentration (nM) was thus determined
using a standard curve of NaNO
2
.
2.10. Lipid Peroxidation Assay. Malonyl dialdehyde (MDA)
was measured by the thiobarbituric acid colorimetric assay
in mice hippocampal homogenates obtained from the brains
of vehicle-, A𝛽-, and pentamidine-treated mice. Briefly, 1mL
trichloroacetic acid 10% was added to 450 𝜇L of tissue lysate.
After centrifugation, 1.3mL thiobarbituric acid 0.5% was
added and the mixture was heated at 80∘C for 20min. After
cooling, MDA formation was recorded (absorbance 530 nm
and absorbance 550 nm) in a PerkinElmer (Waltham, MA,
USA) spectrofluorometer and the results were presented as
ng MDA/mL.
2.11. Enzyme-Linked Immunosorbent Assay (ELISA) for
Prostaglandin (PGE)2, S100B, and Interleukin- (IL-) 1beta (𝛽).
ELISA for PGE2, IL-1𝛽, and S100B (all from R&D Systems,
Minneapolis, Minnesota, USA) was carried out on mouse
hippocampal homogenates, obtained from the brains of
vehicle-, A𝛽-, and pentamidine-treated mice, according to
the manufacturer’s protocol. Absorbance was measured on a
microtiter plate reader. PGE2, IL-1𝛽, and S100B levels were
determined using standard curves method.
2.12. Statistical Analysis. Results were expressed as mean ±
SEM of 𝑛 experiments. Statistical analysis was performed
using analysis of variance (ANOVA) and multiple compar-
isons were performed by Bonferroni’s test, with𝑃 < 0.05 con-
sidered as significant.
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3. Results
3.1. Pentamidine Attenuates A𝛽-Induced Gliosis and Neuroin-
flammation in Hippocampi. Immunoblot analysis showed
that A𝛽 injection significantly increased the expression of
GFAP (34.0 ± 1.6 versus 11.0 ± 1.2, 𝑃 < 0.001, Figures
1(a) and 1(b)), iNOS (8.1 ± 0.9 versus 1.6 ± 0.6, 𝑃 < 0.001,
Figures 1(a) and 1(c)), p-p38 MAP-kinase (8.6 ± 0.8 versus
1.2 ± 0.5, 𝑃 < 0.001, Figures 1(a) and 1(d)), and COX-2
(9.0 ± 0.8 versus 1.0 ± 0.2, 𝑃 < 0.001, Figures 1(a) and 1(e))
proteins in hippocampal homogenates, compared to vehicle-
treated mice. In the same way, also extracellular RAGE
protein expression was significantly increased (11.0 ± 0.8
versus 2.1 ± 0.6, 𝑃 < 0.001, Figures 1(a) and 1(f)) in the hip-
pocampi of A𝛽-injected compared to vehicle-treated mice.
Treatment with pentamidine (0.05–5𝜇g/mL/day) for 7 days,
markedly and in dose-dependent manner blunted A𝛽-
induced overexpression of GFAP (24.0 ± 2.3, 20.0 ± 2.0 and
14.0 ± 2.0 versus 34.0.3 ± 1.6, 𝑃 < 0.05, 0.01 and 0.001,
resp., Figures 1(a) and 1(b)), iNOS (5.0 ± 0.5, 3.2 ± 0.3 and
2.0 ± 0.6 versus 8.1 ± 0.9, 𝑃 < 0.05, 0.01 and 0.001, resp.,
Figures 1(a) and 1(c)), p-p38 MAPK (5.2 ± 1.0, 3.1 ± 0.7 and
2.0 ± 0.6 versus 8.5 ± 0.8, 𝑃 < 0.05, 0.01 and 0.001, resp.,
Figures 1(a) and 1(d)), and COX-2 (6.0 ± 0.5, 4.0 ± 0.5 and
1.2 ± 0.4 versus 9.0 ± 0.8, 𝑃 < 0.05, 0.01 and 0.001, resp.,
Figures 1(a) and 1(e)) in hippocampi homogenates, compared
to A𝛽-treatedmice.The expression of the extracellular RAGE
was also significantly and concentration-dependent reduced
by pentamidine treatment (0.05–5microg/mL/day) for 7 days
(7.0 ± 1.0, 5.2 ± 1.0 and 3.1 ± 1.0 versus 11.0 ± 0.4,𝑃 < 0.05, 0.01
and 0.001, resp., Figures 1(a) and 1(f)).
At nuclear level, A𝛽 injection induced a significant
upregulation of NF-𝜅B (17.5 ± 1.9 versus 1.3 ± 0.8, 𝑃 < 0.001,
Figures 2(a) and 2(b)) compared to vehicle-treated mice,
as demonstrated by EMSA analysis, indicating a marked
A𝛽-induced neuroinflammatory response in the hippocampi
(Figures 2(a) and 2(b)). Pentamidine-mediated inhibitory
effect was observed also for NF-𝜅B in the nuclear extracts,
which was significantly and dose dependently downregulated
(10.6 ± 2.0, 8.4 ± 1.5 and 4.4 ± 1.4 versus 17.5 ± 1.9, 𝑃 < 0.05,
0.01 and 0.001, resp., Figures 2(a) and 2(b)).
As expected, lipid peroxidation assay and Griess reaction
showed that A𝛽 injection area caused a significant increase
of nitrite (15.6 ± 1.9 versus 2.0 ± 0.8, 𝑃 < 0.001, Figure 3(a))
and MDA (8.0 ± 0.8 versus 0.6 ± 0.1, 𝑃 < 0.001, Figure 3(b))
in the hippocampi of A𝛽-treated mice, as a sign of ongoing
inflammation. ELISA also showed that PGE2 (8.7±0.4 versus
0.7 ± 0.1, 𝑃 < 0.001, Figure 3(c)), IL-1𝛽 (6.8 ± 1.0 versus
0.7 ± 0.1, 𝑃 < 0.001, Figure 3(d)), and S100B (6.1 ± 1.2
versus 2.0 ± 1.0, 𝑃 < 0.001, Figure 3(e)) released in the
hippocampi of A𝛽-injected mice were significantly increased
compared to vehicle-treated mice. In line with immunoblot
analysis, pentamidine treatment (0.05–5 𝜇g/mL/day) for 7
days caused a marked and dose-dependent attenuation of
all the abovementioned proinflammatory markers in the
hippocampi: nitrite (11.3±1.4, 8.1±1.5 and 4.4±1.4,𝑃 < 0.05,
0.01 and 0.001, resp., Figure 3(a)); MDA (4.7 ± 0.8, 2.0 ±
0.5 and 0.9±0.3 versus 8.0±0.8,𝑃 < 0.05, 0.01 and 0.001, resp.,
Figure 3(b)); PGE2 (6.0±1.0, 2.8±0.8 and 1.0±0.4, 𝑃 < 0.05,
0.01 and 0.001, resp., Figure 3(c)); and IL-1𝛽 (3.9±0.8, 1.9±0.8
and 1.2±0.4,𝑃 < 0.01 and 0.001, resp., Figure 3(d)) compared
to A𝛽-treated mice. Only the release of S100B remained
unaffected (5.8±1.3, 5.8±1.3 and 5.9±1.2, resp., all 𝑃 > 0.05,
Figure 3(e)) in pentamidine-treated compared to A𝛽-treated
mice.
3.2. Pentamidine Inhibits Reactive Gliosis, Reduces Astrocyte
Infiltration, and Rescues Neuronal Loss in A𝛽-Injected Mice.
A𝛽 injection caused amarked glia activation, as shown by the
increased expression of the astrocytic marker GFAP (153±25
versus 23 ± 5.8, 𝑃 < 0.001, Figures 4(a) and 4(d)). In parallel,
Nissl staining indicated that A𝛽 injection caused a severe
neuronal loss, especially in the CA1 area (site of injection),
compared to vehicle-treated mice (79±5.0 versus 5.6±2, 𝑃 <
0.001, Figures 4(b) and 4(e)). Treatment with pentamidine
(0.05–5𝜇g/mL/day) for 7 days concentration dependently
rescued neurons integrity in the CA1 area (58 ± 4.1, 42 ± 7.0
and 22±5.0 versus 79±5.0, 𝑃 < 0.01 and 0.001, resp., Figures
4(b) and 4(e)).
The neuroprotective effect exerted by pentamidine was
confirmed by FJB analysis. A𝛽 injection caused a significant
increase of FJB-positive cell number in CA1 area versus
vehicle-treated mice (711 ± 102 versus 101 ± 52, 𝑃 <
0.001 Figures 4(c) and 4(f)). Treatment with pentamidine
(0.05–5𝜇g/mL/day) for 7 days reduced in a concentration-
dependent way the number of dying neurons caused by A𝛽
injection in the same area (352 ± 100, 201 ± 95 and 141 ± 71
versus 101 ± 52, 𝑃 < 0.01 and 0.001 resp., Figures 4(c) and
4(f)).
The neuroprotective effect of pentamidine was accom-
panied by a significant downregulation of gliosis grade, as
shown by the concentration-dependent decrease of GFAP
expression (84.6 ± 16, 53 ± 9.6 and 44.2 ± 15, 𝑃 < 0.01 and
0.001, resp.), compared to the hippocampi of A𝛽-treatedmice
(Figures 4(a) and 4(d)). According to the immunohistochem-
istry, immunofluorescence analysis of GFAP and p53 protein
revealed that, after A𝛽 injection, GFAP+ cell number was
significantly increased in the hippocampi of A𝛽-compared to
vehicle-treated mice (41±6.0 versus 13.0±3.0, 𝑃 < 0.01, Fig-
ures 5(a) and 5(b)). Conversely, p53 expression in A𝛽-treated
mice was significantly reduced compared to vehicle-treated
mice (3.2±0.8 versus 9.0±1, 𝑃 < 0.01, Figures 5(a) and 5(b)),
very likely as the consequence of astrocytes infiltration. Treat-
mentwith pentamidine (0.05–5𝜇g/mL/day) for 7 days caused
a dose-dependent decrease of glial cells as indicated by GFAP
positive cell infiltration in CA1 area (30 ± 6.0, 16.0 ± 6.0 and
12.0±3.0 versus 41±6.0,𝑃 < 0.05 and 0.001, resp., Figures 5(a)
and 5(b)) and in the same time it resulted in a dose-dependent
increase of nuclear p53 expression in GFAP expressing cells
(16.0 ± 5.0, 24.0 ± 6.0 and 31.2 ± 3.0 versus 3.2 ± 0.8, 𝑃 < 0.01
and 0.001 resp., Figures 5(a) and 5(b)).
4. Conclusions
Novel therapeutic approaches for the treatment of AD pro-
gression should direct towards the (re)discovery of new
molecules able to have an impact on several pathological
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Figure 1: (a) Western blot and (b–f) densitometric analysis (arbitrary units normalized on the expression of the housekeeping protein 𝛽-
actin) showing the effect of 7 days of intrahippocampal injection of pentamidine (0.05–5𝜇g/mL/day) on GFAP (b), iNOS (c), p-p38 MAPK
(d), COX-2 (e), and RAGE (f) expression in A𝛽-injected mice. Results are expressed as mean ± SEM of 𝑛 = 5 experiments performed in
triplicate. ∗∗∗𝑃 < 0.001 versus vehicle-treated mice; ∘𝑃 < 0.05, ∘∘𝑃 < 0.01 and ∘∘∘𝑃 < 0.001 versus A𝛽-treated mice.
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Figure 2: (a) Electrophoretic mobility shift assay (EMSA) and the relative (b) densitometric analysis showing the effect following 7 days of
intrahippocampal injection of pentamidine (0.05–5𝜇g/mL/day) on the expression of NF-𝜅B in A𝛽-injected mice. Results are expressed as
mean ± SEM of 𝑛 = 5 experiments performed in triplicate. ∗∗∗𝑃 < 0.001 versus vehicle-treated mice; ∘∘𝑃 < 0.01 and ∘∘∘𝑃 < 0.001 versus
A𝛽-treated mice.
pathways that together converge to the progressive neurolog-
ical decline characteristic of the disease. Inflammation, more
specifically neuroinflammation, has been widely known as
an accompanying and key feature in AD [24–26]. In fact,
both in vitro and in vivo studies have shown that A𝛽, the
major constituent of the senile plaques in the AD brain, can
directly or indirectly activate the secretion of proinflam-
matory cytokines [27]. Therefore, the search for new drugs
should be based on diverse targets in the attempt to blunt the
inflammatory scenario in the AD brain and not only to
replace the neurotransmission failure.
Here we show that pentamidine, an ancient antiprotozoal
drug that inhibits S100B protein, ameliorates gliosis and
neuroinflammation in a mouse model of A𝛽-induced AD.
Many studies have been addressed in the attempt to enlarge
the pharmacological knowledge on pentamidine and its novel
therapeutic effects in disorders characterized by S100B upreg-
ulation, such asmelanoma [28], glioblastoma [29], and colitis
[19]. This has led to the discovery that, besides being an
antiprotozoal drug, pentamidine also inhibits S100B activity
by blocking the interaction at the Ca++/p53 site of the protein.
S100B is a unique glial-derived factor in the sense that it
is responsible for the establishment of neuroinflammation
and neurodegeneration [30]. In fact, in AD brains, S100B
is released by reactive astrocytes, a phenomenon known as
“reactive gliosis,” and promotes the formation of neurofib-
rillary tangles in a RAGE-dependent manner [31]. Once
released, S100B accumulates at the RAGE [15, 32] and this
interaction leads to the induction of lipid peroxidation and
to MAPK phosphorylation that in turn converge to NF-𝜅B
activation. By triggering this pathway, S100B induces the
transcription of proinflammatory proteins and cytokines,
such as iNOS protein, IL-1𝛽, and TNF𝛼 [33, 34]. It is thus
conceivable that, by specifically targeting the RAGE/S100B
interaction in the brain, it would be possible to inhibit S100B-
dependent neuroinflammation in AD. Different studies have
suggested that a possible therapeutic approach might be the
inhibition of the binding of S100B to the V domain of RAGE
by using specific antibodies or smallmolecules [35].However,
since RAGE is not the sole receptormediating S100B effects, it
seems more logic to inhibit the protein itself before it binds
to any target. The results of this study demonstrate that pen-
tamidine, via direct inhibition of S100B protein, attenuates
1/reactive gliosis and neuroinflammation induced by A𝛽 in
mouse hippocampi and 2/neuronal loss in the CA1 area of
the brain. Specifically, pentamidine caused a dose-dependent
decrease of GFAP protein expression, a sign of gliosis, in
mice hippocampal homogenates. This was accompanied by
the dose-dependent inhibition of iNOS, COX-2, and p-p38
MAPKprotein expression. Consequently to S100B inhibition,
pentamidine indirectly interferes with S100B-RAGE inter-
action, leading to a marked inhibition of RAGE protein
expression, which was upregulated after A𝛽 injection. This
result caused the interruption of the downstream RAGE-
dependent effects such as NF-𝜅B mobilization in the cytosol
and the consequent induction of transcription of proinflam-
matory signalingmolecules/cytokines. At confirmation of the
amelioration of the inflammatory scenario, pentamidine was
also able to reduce the release of proinflammatory cytokines,
namely, PGE2 and IL-1𝛽. Moreover, we demonstrated that
pentamidine inhibited other proinflammatory events like
lipid peroxidation and nitric oxide release. According to our
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Figure 3: Effect of pentamidine on release of nitrites (a), MDA (b), PGE2 (c), IL-1𝛽 (d), and S100B (e) in hippocampal homogenates of A𝛽-
injected mice. Results are expressed as mean ± SEM of 𝑛 = 5 experiments performed in triplicate. ∗∗∗𝑃 < 0.001 versus vehicle-treated mice;
∘
𝑃 < 0.05, ∘∘𝑃 < 0.01 and ∘∘∘𝑃 < 0.001 versus A𝛽-treated mice.
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Figure 4: (a) Immunohistochemistry analysis showing the effect of pentamidine in hippocampal coronal sections after A𝛽 injection. The
upper panel shows GFAP-positive cells (astrocytes) infiltrating the hippocampi. Note the increased number of GFAP-positive cells in A𝛽-
treated (2) compared to vehicle-treated mice (1) and the dose-dependent reduction after pentamidine treatment (3-4-5). Scale bar: 200𝜇m.
(b) Nissl staining showing the effect of pentamidine on pyramidal neuron loss in the CA1 area after A𝛽 injection. Note the reduced number of
neurons stained in A𝛽-treated (2) compared to vehicle-treated mice (1) and the dose-dependent reduction of neuronal loss after pentamidine
treatment (3-4-5). Scale bar: 200 𝜇m. (c) Immunofluorescence analysis showing the effect of pentamidine in hippocampal coronal sections
after A𝛽 injection. Note the reduced number of neurons after A𝛽 injection (2) compared to vehicle-treated mice (1) and the dose-dependent
neuroprotection after pentamidine treatment (3-4-5). Scale bar: 200𝜇m. (d) Relative quantification of GFAP expression, (e) extent of CA1
damage measurement, and (f) number of neurons stained with Fluorojade B (FJB) in the hippocampi. Results are expressed as mean ± SEM
of 𝑛 = 5 experiments performed in triplicate. ∗∗∗𝑃 < 0.001 versus vehicle-treated mice; ∘∘𝑃 < 0.01 and ∘∘∘𝑃 < 0.001 versus A𝛽-treated mice.
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Figure 5: Effect of pentamidine (0.05–5𝜇g/mL/day) on GFAP and p53 expression in astrocyte in the hippocampi of A𝛽-injected mice. (a)
Immunofluorescence analysis of hippocampal coronal sections. Note the increasedGFAP expression in hippocampal astrocytes of A𝛽-treated
(2) compared to vehicle-treatedmice (1) and the dose-dependent reduction after pentamidine treatment (3-4-5). Scale bar: 50𝜇m. (b) Relative
quantification of p53-positive/GFAP-positive (open bars) and p53-positive/GFAP-positive (filled bars) astrocytes in the CA1 area of the brain.
Results are expressed as mean ± SEM of 𝑛 = 4 experiments performed in triplicate. ∗∗∗𝑃 < 0.001 versus vehicle-treated mice; ∘𝑃 < 0.05 and
∘∘∘
𝑃 < 0.001 versus A𝛽-treated mice. §§𝑃 < 0.01 versus vehicle-treated mice; ##𝑃 < 0.01, ###𝑃 < 0.001 versus A𝛽-treated mice.
previous observations [29], S100Bprotein releasewas upregu-
lated byA𝛽 injection but its level was not affected by pentami-
dine treatment. To prove that all the above discussed anti-
inflammatory effects, together with the reduction of reactive
gliosis, were due to the inhibition of S100B/p53 binding,
we evaluated p53 expression in the different experimental
conditions. We found that the treatment with pentamidine
induced p53 expression on infiltrating astrocytes in mouse
10 BioMed Research International
hippocampi, as sign of enhanced apoptosis. Together with
reduced gliosis, we also observed the rescue of neuronal loss
in the damaged area of the brain.
Though preliminary, our data identifies in pentamidine
a novel potential drug for the treatment of AD features.
However, future studies are needed to investigate whether,
together with its anti-inflammatory and neuroprotective
activity, pentamidine may also improve mnemonic and cog-
nitive performances in experimentalmodels of AD.However,
one of the limiting factors of pentamidine resides in its
pharmacokinetic profile, which is characterized by low
blood brain barrier crossing. Thus, new pharmacokinetic
approaches aimed at increasing the delivery of pentamidine
into the brain, in combination with a suitable compliance in
terms of way of administration, look very intriguing.
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